Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

368

HTML

2360

Figures (1-5)

303

Tables (1-4)

248

Sum=3279

Jun 21, 2006 (publication date) through Feb 8, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jun 21, 2006; 12(23): 3760-3765
Published online Jun 21, 2006. doi: 10.3748/wjg.v12.i23.3760

Full Size Figure Download Figure

Figure 4 Post-recurrence survival rate of 55 small bowel GIST patients treated with and without Glivec.

Citation: Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate. World J Gastroenterol 2006; 12(23): 3760-3765
URL: https://www.wjgnet.com/1007-9327/full/v12/i23/3760.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i23.3760